Hologic Company Profile (NASDAQ:HOLX)

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:HOLX
  • CUSIP: 43644010
  • Web: www.hologic.com
Capitalization:
  • Market Cap: $12.6 billion
  • Outstanding Shares: 280,010,000
Average Prices:
  • 50 Day Moving Avg: $45.08
  • 200 Day Moving Avg: $42.70
  • 52 Week Range: $35.15 - $46.80
P/E:
  • Trailing P/E Ratio: 16.14
  • Foreward P/E Ratio: 20.37
  • P/E Growth: 2.28
Sales & Book Value:
  • Annual Revenue: $2.89 billion
  • Price / Sales: 4.36
  • Book Value: $10.00 per share
  • Price / Book: 4.50
Profitability:
  • EBIDTA: $1.01 billion
  • Net Margins: 27.31%
  • Return on Equity: 25.26%
  • Return on Assets: 7.59%
Debt:
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 0.86%
  • Quick Ratio: 0.70%
Misc:
  • Average Volume: 2.63 million shs.
  • Beta: 0.91
  • Short Ratio: 2.66
 

Frequently Asked Questions for Hologic (NASDAQ:HOLX)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings results on Wednesday, May, 10th. The company reported $0.50 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.46 by $0.04. The business had revenue of $715.40 million for the quarter, compared to analyst estimates of $685.24 million. Hologic had a return on equity of 25.26% and a net margin of 27.31%. Hologic's quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 EPS. View Hologic's Earnings History.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY17 earnings guidance on Wednesday, May, 10th. The company provided EPS guidance of $1.98-2.02 for the period, compared to the Thomson Reuters consensus estimate of $1.98. The company issued revenue guidance of $3.05-3.08 billion, compared to the consensus revenue estimate of $3.06 billion.Hologic also updated its Q3 guidance to $0.48-0.50 EPS.

Where is Hologic's stock going? Where will Hologic's stock price be in 2017?

13 analysts have issued 1-year target prices for Hologic's stock. Their predictions range from $39.00 to $53.00. On average, they expect Hologic's stock price to reach $47.69 in the next year. View Analyst Ratings for Hologic.

What are analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

  • 1. According to Zacks Investment Research, "Hologic witnessed a lackluster performance at its Diagnostics segment in the last reported quarter. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges. On a positive note, the company has been registering strong top line growth in recent times driven by strength in molecular diagnostics, GYN Surgical and Breast Health businesses. The company's raised guidance for fiscal 2017 indicates that this growth momentum should continie through rest of the year.  In fact, the recent European approval for the company's new Panther system should boost growth in the coming quarter. For the last three months, Hologic has been trading above the broader Medical Instruments industry in terms of price. Hologic’s strong cash position is another encouraging factor." (7/12/2017)
  • 2. Needham & Company LLC analysts commented, "HOLX is acquiring Cynosure (CYNO) for $1.44B with an all-cash tender offer. CYNO is a leading aesthetics company that competes in a $2B market growing in the double-digits with a range of products used for hair removal, body contouring, skin revitalization, and other cosmetic procedures. HOLX expects CYNO to increase its revenue growth and add $0.13-0.15 to its FY18E EPS. HOLX has now effectively swapped a business with declining sales and margins (blood screening) for one with double-digit growth and improving margins (CYNO). With the blood screening EPS "hole" now partially filled and HOLX facing increasingly easy comps over the next three quarters, we upgrade to Buy." (2/15/2017)

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

  • Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer
  • Robert W. McMahon, Chief Financial Officer
  • Sanjay Prabhakaran, Regional President - Asia
  • Peter J. Valenti III, Division President- Breast and Skeletal Health
  • Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
  • Thomas A. West, Division President- Diagnostics
  • Eric B. Compton, Chief Operating Officer
  • Michael J. Watts, Vice President, IR Contact Officer
  • John M. Griffin, General Counsel
  • Elaine S. Ullian, Lead Independent Director

Who owns Hologic stock?

Hologic's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (1.22%), Ardevora Asset Management LLP (0.28%), First Quadrant L P CA (0.23%), Gateway Investment Advisers LLC (0.18%), GW&K Investment Management LLC (0.14%) and National Pension Service (0.10%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III, Sally Crawford and Wayne Wilson. View Institutional Ownership Trends for Hologic.

Who sold Hologic stock? Who is selling Hologic stock?

Hologic's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Nisa Investment Advisors LLC, Creative Planning, Exxonmobil Investment Management Inc. TX, Chemung Canal Trust Co., Webster Bank N. A., Capstone Asset Management Co. and Eqis Capital Management Inc.. Company insiders that have sold Hologic stock in the last year include Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, First Quadrant L P CA, GW&K Investment Management LLC, Ardevora Asset Management LLP, Mn Services Vermogensbeheer B.V., National Pension Service, DnB Asset Management AS and NN Investment Partners Holdings N.V.. View Insider Buying and Selling for Hologic.

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of Hologic stock can currently be purchased for approximately $45.01.


MarketBeat Community Rating for Hologic (NASDAQ HOLX)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  489 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  804
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hologic (NASDAQ:HOLX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $47.69 (5.96% upside)

Analysts' Ratings History for Hologic (NASDAQ:HOLX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Bank of America CorporationReiterated RatingNeutral$44.00 -> $48.00LowView Rating Details
7/17/2017Barclays PLCReiterated RatingOverweight$50.00 -> $53.00LowView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$51.00MediumView Rating Details
7/14/2017Stifel NicolausReiterated RatingBuyMediumView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingBuy$49.00LowView Rating Details
5/14/2017BTIG ResearchReiterated RatingBuy$47.00LowView Rating Details
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00LowView Rating Details
4/4/2017Needham & Company LLCBoost Price TargetBuy -> Buy$46.00 -> $50.00MediumView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingBuy$48.00N/AView Rating Details
1/4/2017Evercore ISIDowngradeBuy -> Hold$42.00N/AView Rating Details
8/1/2016Royal Bank Of CanadaReiterated RatingSector Perform$37.00 -> $39.00N/AView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
4/29/2016Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy -> Buy$45.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
1/28/2016J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/26/2015GabelliInitiated CoverageBuy$43.00N/AView Rating Details
10/21/2015Craig HallumDowngradeBuy -> Hold$42.00 -> $37.00N/AView Rating Details
8/3/2015ArgusReiterated RatingBuy$43.00 -> $52.00N/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Hologic (NASDAQ:HOLX)
Earnings by Quarter for Hologic (NASDAQ:HOLX)
Earnings History by Quarter for Hologic (NASDAQ HOLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hologic (NASDAQ:HOLX)
2017 EPS Consensus Estimate: $2.01
2018 EPS Consensus Estimate: $2.33
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$0.50$0.51$0.51
Q2 20173$0.46$0.53$0.49
Q3 20173$0.48$0.54$0.50
Q4 20173$0.49$0.55$0.52
Q1 20181$0.54$0.54$0.54
Q2 20181$0.57$0.57$0.57
Q3 20181$0.60$0.60$0.60
Q4 20181$0.62$0.62$0.62
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Hologic (NASDAQ:HOLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hologic (NASDAQ:HOLX)
Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 94.04%
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.72View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.40View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.62View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.20View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.49View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.80View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.58View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.00View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.04View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.64View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.65View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.60View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.42View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.36View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.05View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.88View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.66View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.68View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.00View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.00View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.84View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.54View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.26View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.60View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.80View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.50View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.00View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.00View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.00View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.20View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.80View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.32View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.68View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.03View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.90View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.00View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.40View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.00View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.28View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hologic (NASDAQ:HOLX)
Latest Headlines for Hologic (NASDAQ:HOLX)
Source:
DateHeadline
finance.yahoo.com logoInside Abiomed’s Profit Margin Expectations for Fiscal 2018
finance.yahoo.com - July 21 at 3:59 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Earns "Neutral" Rating from Bank of America Corporation
www.americanbankingnews.com - July 21 at 9:30 AM
americanbankingnews.com logoHologic, Inc. (NASDAQ:HOLX) VP Sells $212,573.76 in Stock
www.americanbankingnews.com - July 19 at 7:38 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Stock Rating Reaffirmed by Barclays PLC
www.americanbankingnews.com - July 17 at 10:20 PM
americanbankingnews.com logoPiper Jaffray Companies Reaffirms "Buy" Rating for Hologic, Inc. (HOLX)
www.americanbankingnews.com - July 15 at 9:44 AM
americanbankingnews.com logoHologic's (HOLX) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - July 15 at 7:26 AM
finance.yahoo.com logoETFs with exposure to Hologic, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 12:23 AM
finance.yahoo.com logoHologic, Inc. breached its 50 day moving average in a Bearish Manner : HOLX-US : July 12, 2017
finance.yahoo.com - July 12 at 9:07 PM
americanbankingnews.com logoZacks Investment Research Downgrades Hologic, Inc. (NASDAQ:HOLX) to Sell
www.americanbankingnews.com - July 12 at 8:26 PM
finance.yahoo.com logoZacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
finance.yahoo.com - July 10 at 7:32 PM
americanbankingnews.com logoInsider Selling: Hologic, Inc. (HOLX) Director Sells 8,849 Shares of Stock
www.americanbankingnews.com - July 6 at 7:41 PM
finance.yahoo.com logoHologic to Announce Financial Results for the Third Quarter of Fiscal 2017 on Wednesday, August 2, 2017
finance.yahoo.com - July 5 at 8:11 PM
americanbankingnews.com logoZacks: Analysts Expect Hologic, Inc. (HOLX) Will Post Quarterly Sales of $798.96 Million
www.americanbankingnews.com - June 30 at 1:44 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 10:10 AM
finance.yahoo.com logoHologic's New Panther Fusion® System, Flu and Respiratory Assays Now CE Marked in Europe
finance.yahoo.com - June 29 at 11:54 PM
nasdaq.com logoHologic (HOLX) Product Pipeline Strong, Competition Rife - Nasdaq
www.nasdaq.com - June 28 at 7:05 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Hologic, Inc. (HOLX) Will Post Earnings of $0.49 Per Share
www.americanbankingnews.com - June 28 at 4:10 PM
americanbankingnews.com logoHologic's (HOLX) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - June 28 at 11:28 AM
finance.yahoo.com logoHologic Looks Good on the Charts
finance.yahoo.com - June 27 at 5:55 PM
nasdaq.com logoHOLX Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - June 24 at 1:49 AM
nasdaq.com logoHologic (HOLX) Gets FDA Clearance for Aptima HSV 1 & 2 Test - Nasdaq
www.nasdaq.com - June 21 at 3:17 PM
finance.yahoo.com logoHologic (HOLX) Gets FDA Clearance for Aptima HSV 1 & 2 Test
finance.yahoo.com - June 21 at 3:17 PM
streetinsider.com logoHologic (HOLX) Announces FDA Clearance of Aptima Assay to ... - StreetInsider.com
www.streetinsider.com - June 21 at 1:20 AM
finance.yahoo.com logoHologic Announces FDA Clearance of Aptima® Assay to Detect Herpes Simplex Virus 1 & 2
finance.yahoo.com - June 20 at 3:18 PM
streetinsider.com logoHologic (HOLX) Granted Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure for Non-Invasive Body Contouring (Lipolysis)
www.streetinsider.com - June 17 at 2:08 AM
seekingalpha.com logoHologic (HOLX) Presents At The William Blair 2017 Growth Stock Conference - Slideshow
seekingalpha.com - June 16 at 6:33 PM
finance.yahoo.com logoETFs with exposure to Hologic, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 6:33 PM
finance.yahoo.com logoHologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure® for Non-Invasive Body Contouring (Lipolysis) of Back, Inner and Outer Thighs
finance.yahoo.com - June 15 at 7:57 PM
nasdaq.com logoHologic (HOLX) Up 3.5% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - June 14 at 7:28 PM
finance.yahoo.com logoHologic (HOLX) Up 3.5% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 14 at 11:39 AM
americanbankingnews.com logoHologic, Inc. (HOLX) Short Interest Update
www.americanbankingnews.com - June 11 at 7:22 AM
americanbankingnews.com logoLawrence M. Levy Sells 2,960 Shares of Hologic, Inc. (HOLX) Stock
www.americanbankingnews.com - June 9 at 10:34 AM
streetinsider.com logoHologic (HOLX) Announces FDA Approval for Genius 3D Mammography Exam
www.streetinsider.com - June 8 at 3:19 AM
streetinsider.com logoHologic (HOLX) Announces FDA Approval for Genius 3D Mammography Exam - StreetInsider.com
www.streetinsider.com - June 7 at 10:31 AM
finance.yahoo.com logoFDA Approves Hologic's Genius™ 3D Mammography™ Exam as the Only Mammogram Superior for Women with Dense Breasts*
finance.yahoo.com - June 7 at 10:31 AM
americanbankingnews.com logoInsider Selling: Hologic, Inc. (HOLX) Director Sells 8,938 Shares of Stock
www.americanbankingnews.com - June 6 at 7:51 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 5 at 9:57 AM
americanbankingnews.com logo$798.96 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - June 4 at 8:42 AM
finance.yahoo.com logoETFs with exposure to Hologic, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 7:07 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Hologic, Inc. (HOLX) to Post $0.49 Earnings Per Share
www.americanbankingnews.com - June 2 at 2:36 PM
finance.yahoo.com logoHologic, Inc. :HOLX-US: Earnings Analysis: Q2, 2017 By the Numbers : June 1, 2017
finance.yahoo.com - June 1 at 6:32 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Insider Sells $434,617.20 in Stock
www.americanbankingnews.com - May 31 at 7:45 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Given a $49.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - May 30 at 12:46 AM
finance.yahoo.com logoHologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : May 26, 2017
finance.yahoo.com - May 26 at 6:25 PM
finance.yahoo.com logoPost Earnings Coverage as Hologic's Q2 Results Outperformed Expectations
finance.yahoo.com - May 26 at 6:25 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Director Lawrence M. Levy Sells 9,193 Shares
www.americanbankingnews.com - May 26 at 10:35 AM
finance.yahoo.com logoHalyard Health (HYH) Expands CORGRIP System Product Line
finance.yahoo.com - May 23 at 5:19 PM
americanbankingnews.com logoHologic, Inc. (HOLX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 23 at 1:52 PM
americanbankingnews.com logoInsider Selling: Hologic, Inc. (HOLX) Director Sells 9,076 Shares of Stock
www.americanbankingnews.com - May 19 at 10:22 AM
finance.yahoo.com logoMazor Robotics at a 52-Week High: What's Driving the Stock?
finance.yahoo.com - May 19 at 10:15 AM

Social

Chart

Hologic (HOLX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff